65,437 trials
Clostridium Difficile Infection Recurrence · Clostridium Difficile Infection · Clostridium Difficile
Primary: CDI Recurrence Week 8 — 4; 9; 5; 4 Participants
Porphyria Cutanea Tarda · Hepatitis C
Primary: Number of Participants With Resolution of Active PCT by 7 Months After Start of Therapy — 9 Participants
Relapsing-Remitting Multiple Sclerosis (RRMS)
Primary: Cumulative Number of New Active Lesions Over 24 Weeks — 1.4; 1.9; 1.4; 2.1 lesions
Actinic Keratosis
Primary: Participant Complete Response Rate (CRR) — 68.4; 6.9 Percentage of participants
Allergic Rhinitis · Allergic Rhinoconjunctivitis
Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects
Prurigo Nodularis · Pruritus · Chronic Pruritus
Primary: Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12 — -78.26; -53.66 percent change — p=<0.001
HIV Infections
Primary: The Percentage of Participants Who Report Willingness to Use the Study Regimen, Take up PrEP, and Remain on PrEP as Part of a Comprehensive Prevention Package — 148…
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline at Week 32 in Peak V02 Consumption in Verinurad + Allopurinol Compared to Placebo (ANCOVA Model) — 0.27; 0.37 mL/kg/min — p=0.862
COVID-19
Primary: Percentage of Participants With Disease Progression Using National Institute of Allergy and Infectious Diseases (NIAID) 8-point Ordinal Scale at Day 14 — 9.8; 11.6…
Acute Kidney Injury
Primary: Percentage of Patients With Progression of AKI OR Dialysis OR Death — 639; 585 Participants
HIV Infection · Alcohol Consumption · Falls, Accidental
Primary: Engagement With Intervention — 3.27 intervention sessions
Biliary Tract Cancer
Primary: Progression Free Survival (PFS) — 7.92; 8.35 Months
Hereditary Angioedema
Primary: Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period — 0.27; 2.01 number of HAE attacks per month — p=<0.001
Immunotherapy · Allergy
Primary: Change in Patient Pain Perception Utilizing Three Non-pharmacological Pain Control / Distraction Devices and Ethyl Chloride Spray — 1.33; 2.22; 2.25; 1.45 score on a scale
Depression, Anxiety · Stress
Primary: Change in Salivary Cortisol Levels — 0.07; 0.11 ug/dl